PreveCeutical Medical (TSE:PREV) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PreveCeutical Medical Inc.’s subsidiary, BioGene Therapeutics, has appointed Dr. Brian Gallagher, Jr. to its Corporate Advisory Board, bringing his expertise in venture capital and corporate development. Gallagher’s extensive experience in biotech investments and successful leadership in high-profile exits, like the acquisition of Translate Bio by Sanofi, is expected to drive BioGene’s growth in innovative therapies.
For further insights into TSE:PREV stock, check out TipRanks’ Stock Analysis page.